UPC
UniverseCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The June 2026 acquisition could provide optionality through early-stage pharmaceutical intellectual property and potential licensing, co-development, or commercialization opportunities [#PR-2026-06-26].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
No confirmed 2026 earnings release, guidance, transcript, or analyst revision was located.
Momentum
69
Value
46
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.00 · Bull $6.50 · Bear $2.75
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum69 · Δ7d -
Value46 · Δ7d +0.0
Sentiment37 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
69
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
37
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 68.7 / Value 46.4 / Sentiment 37.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$2.68M
Beta
1.51
Shares Out
631.76K
P/E (TTM)
0.0
P/S (TTM)
0.12
P/FCF (TTM) · Derived
-0.63
Rev YoY
-29.0%
EPS YoY
+99.6%
Gross Margin
+35.3%
Op Margin
-44.6%
Net Debt
-$24.34M
Current Ratio
4.07
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology